Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company dedicated to developing innovative products to meet the increasing demand for the use of radiopharmaceuticals in oncology. With a focus on personalized medicine, Clarity is a leader in the field of targeted therapies for the treatment of cancer and other serious diseases in both adults and children. At Clarity, our mission is to develop next-generation radiopharmaceutical products that enhance treatment outcomes for individuals with cancer.

Our proprietary SAR Technology platform, utilizing copper isotopes, enables the development of highly targeted theranostic (therapy and imaging) radiopharmaceuticals. This technology overcomes current manufacturing and logistical limitations, allowing for superior imaging and therapeutic capabilities. Clarity's clinical development pipeline includes a range of products targeting large cancer indications such as prostate and breast cancer, as well as rare and orphan cancer indications like neuroblastoma.

Our lead product, SARTATE™, is currently in clinical trials for neuroblastoma and neuroendocrine tumors, while SAR-bisPSMA is being developed as a stand-alone diagnostic and theranostic product for prostate cancer. Additionally, SAR-Bombesin is being developed as a pan-cancer theranostic radiopharmaceutical. Stay up-to-date with the latest news about Clarity Pharmaceuticals and our groundbreaking advancements in the field of radiopharmaceutical therapies.

Join us in our mission to revolutionize cancer treatment and improve the lives of patients worldwide